Michele M. Luchetti-Gentiloni
Ancona, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Comparative effectiveness and predictors of remission between adalimumab and ixekizumab in patients with psoriatic arthritis: findings from the 'AIRE' multicentre study.
Journal: RMD open
Published: December 28, 2025
Does Prior Exposure Affect Retention? A Real-World, Multicentre Assessment of IL-17 Inhibitor Cycling in Psoriatic Arthritis.
Journal: Rheumatology and therapy
Published: December 22, 2025
Real-world clinical experience with upadacitinib in a cohort of Italian patients with axial spondyloarthritis.
Journal: Frontiers in pharmacology
Published: November 29, 2025
The role of integrated gastro-rheumatological care in IBD-associated Spondyloarthritis in achieving joint-gut remission: Four-year outcomes from the real-world SPIB cohort.
Journal: Seminars in arthritis and rheumatism
Published: October 30, 2025
The pivotal role of Interleukin-23 in the skin-gut-joint axis.
Journal: Journal of autoimmunity
Published: August 12, 2025
Clinical and ultrasound remission at 48 weeks of upadacitinib in rheumatoid arthritis: real-world results from the Italian multicenter UPARAREMUS study.
Journal: Arthritis research & therapy
Published: June 03, 2025
The Impact of Sex on the Pattern and Clinical Response of Early Psoriatic Arthritis: Real-life Data from the Italian Prospective SIRENA Study.
Journal: Rheumatology and therapy
Published: May 28, 2025
Targeting axial and peripheral psoriatic arthritis: a retrospective observational study on the clinical relevance of upadacitinib.
Journal: Rheumatology (Oxford, England)
Published: February 07, 2025
Axial psoriatic arthritis in patients not fulfilling the back pain entry features of the ASAS Classification Criteria for Axial Spondyloarthritis: findings from the ATTRACT Study.
Journal: Rheumatology (Oxford, England)
Published: November 18, 2024
Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis.
Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis.
Journal: Frontiers in immunology
Published: May 20, 2024
Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort.
Journal: Arthritis research & therapy
Published: March 16, 2024
The ATTRACT study: screening for the early identification of axial psoriatic arthritis in a cohort of Italian psoriatic patients.
Journal: Rheumatology (Oxford, England)
Published: August 11, 2023
Last Updated: 09/26/2026